Navigation Links
FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
Date:11/4/2010

INDIANAPOLIS, Nov. 4, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low back pain and chronic pain due to osteoarthritis. This is the fifth indication the FDA has approved for Cymbalta.

Cymbalta, which has been shown to significantly reduce chronic low back pain and chronic pain due to osteoarthritis, is a non-narcotic pain reliever that is meant to be taken once a day, every day by people with these pain conditions.

"People with chronic musculoskeletal pain often struggle to find a medication that works for them. The approval of Cymbalta for chronic musculoskeletal pain by the FDA gives doctors another option to help an underserved and suffering group of patients," said Michael Clark, M.D., MPH, director, Chronic Pain Treatment Program, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins Medical Institutions.

Although the exact way that Cymbalta works to reduce chronic musculoskeletal pain is unknown, it is believed that Cymbalta helps lessen pain by enhancing the body's natural pain suppressing system by increasing the activity of serotonin and norepinephrine in the brain and spinal cord.

In chronic musculoskeletal pain clinical studies, the most commonly observed adverse events (those occurring in at least 5 percent of study participants taking Cymbalta and at least twice the rate of placebo) in Cymbalta-treated patients with chronic low back pain were nausea, dry mouth, insomnia, sleepiness, constipation, dizziness and fatigue. The most commonly observed adverse events in Cymbalta-treated patients with chronic pain due to osteoarthritis were nausea, fatigue and constipation.

"It's important that p
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves New Indication for Afinitor
2. FDA Approves Teflaro for Bacterial Infections
3. FDA Approves Latuda to Treat Schizophrenia in Adults
4. FDA Approves Additional Medical Indication for Sprycel
5. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
6. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
7. FDA Approves Botox to Treat Chronic Migraine
8. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
9. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
10. FDA Approves Combination Contraceptive Containing a Folate
11. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that a ... catalogue: Global Orthopedic Soft Tissue Repair ... About Orthopedic Soft Tissue ... of cells that connect, support, or surround bones. ... such as tendons, ligaments, cartilage, fascia, and other ...
(Date:8/27/2014)...  Decision Resources Group finds that physicians surveyed ... gastroenterology, endocrinology and nephrology) expect the robustness and ... been assessed in to be the strongest influencers ... Other key findings from the ... of Biosimilars Across Physician Specialties : ...
(Date:8/27/2014)... Mass. , Aug. 27, 2014 Decision ... that characterized the Memphis health ... way to clinical integration, with rivals Methodist Le Bonheur ... respective physician groups to coordinate patient care. In addition, ... which has the most health plan enrollment in the ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2Memphis-area Health Systems Turn Attention to Clinical Integration 2
... 2011 Centre Partners Management LLC ("Centre Partners"), a leading ... and Los Angeles, today announced the completion of the sale ... Troy Limited (Nasdaq: HELE). Kaz is an international leader in ... valued at $260 million subject to certain closing working capital ...
... The MED Group, a Managed Health Care Associates, Inc. ...  The website was created to help answer questions for ... about competitive bidding and how patients can receive their ... Centers for Medicare and Medicaid Services (CMS) will be ...
Cached Medicine Technology:Centre Partners Announces Successful Realization of Investment in Kaz, Inc. 2Centre Partners Announces Successful Realization of Investment in Kaz, Inc. 3New Program for Medicare Beneficiaries Will Mean Major Changes Effective January 1, 2011 - Florida 2New Program for Medicare Beneficiaries Will Mean Major Changes Effective January 1, 2011 - Florida 3
(Date:8/27/2014)... 2014 The American College ... the management and treatment of pulmonary arterial hypertension ... Hypertension in Adults: CHEST Guideline, in the journal ... clinicians, and provide the latest and most accurate ... Hypertension Association (PHA) – the country’s leading ...
(Date:8/27/2014)... use of hormone therapy has spawned a prevalent but ... with hot flashes, according to a study by a ... In the study published in the Aug. 27 online ... found that moderate to severe hot flashes also ... most women. Women with VMS experience more than feeling ...
(Date:8/27/2014)... August 27, 2014 Ticket Down ... tickets at Levi’s Stadium in Santa Clara. Levi’s ... Clara, California just opened in July and will host their ... takes on Chile. These are two of the best teams ... World Cup and will look to continue their successes from ...
(Date:8/27/2014)... Sound Telecom, a leading telecommunications company that ... communication systems, has unveiled an article titled “ Three ... Messaging .” The piece examines the world of medical ... remain compliant with HIPAA and HITECH requirements. , ... at Sound Telecom, opens with evidence that the use ...
(Date:8/27/2014)... York (PRWEB) August 27, 2014 Parker ... protecting the rights of victims injured by defective medical ... in place for discovery procedures, specifically Collection and Preservation ... C.R. Bard’s transvaginal mesh devices. (MDL No. 2187, In ... Litigation, the United States District Court, Southern District or ...
Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2Health News:The high cost of hot flashes: Millions in lost wages preventable 2Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 2Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 3Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 2Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4
... Find a Top Doc ... in their community. , ... (PRWEB) November 16, 2009 -- If one wnats to find love, no problem, they just jump ... match. Want to find a great doctor, now that,s another story. For some reason ...
... PharmaShack.com - ... off on all items, and a new and exciting range of new dietary products such ... ... nowadays, some are planning to go on a diet, others have high cholesterol counts, men ...
... ... available in Istanbul Hospitals. Both eyes iLASIK treatment packages including flight tickets and accommodations ... ... announce the iLASIK procedure is now available in Istanbul Hospitals. Both eyes iLASIK treatment ...
... ... Laser Institute announced today that Dr. Jon Dishler has been selected by ... United States for 2009. The list of leading Laser Eye Surgeons of ... Forbes Magazine.,Internationally recognized, leader of numerous FDA laser vision trials, and originator ...
... , NANJING, China, Nov. 16 /PRNewswire-Asia/ ... ), a leading pharmaceutical company,specializing in the development, manufacturing, and marketing ... for the quarter ended September 30, 2009. , , ... (US$65.0 million) for the third, ...
... A study of 145 preschool children reports, for the ... phthalates in mothers, prenatal urine are elevated their sons ... games, such as trucks and play fighting. The ... the International Journal of Andrology . Because ...
Cached Medicine News:Health News:PharmaShack.com Embraces Fall - Offers 15 Percent Off of All Meds on Site 2Health News:iLASIK Treatment Now Available in Istanbul, Turkey at World Eye Hospitals 2Health News:iLASIK Treatment Now Available in Istanbul, Turkey at World Eye Hospitals 3Health News:iLASIK Treatment Now Available in Istanbul, Turkey at World Eye Hospitals 4Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 2Health News:Dishler Laser Institute Announces Dr. Jon Dishler Selected as a Leading Laser Eye Surgeon of the United States, as Seen in Forbes Magazine 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results 12Health News:Pilot study relates phthalate exposure to less-masculine play by boys 2Health News:Pilot study relates phthalate exposure to less-masculine play by boys 3
NEAR-SkinTM Incise Drape Aggressive adhesive with no residue High moisture permeability for extended adhesion Low-glare matte finish film Product number identification...
... and the Penilab V have an exceptionally sensitive plethysmograph ... similar to the Model 1061 shown below, but does ... later. The Penilab V has a Doppler. ... you'll need to get started. Latex rubber cuffs ...
... Model 246 is designed for vascular ... graphic recorders. Its primary use ... studies using a cuff with air. ... using two cuffs - a proximal ...
... SP MRI-Compatible Anesthesia System is perfect for larger ... one type of anesthetic agent. , ,The ... to its wider stance, has a larger work ... assembly is utilized in both the Integra I ...
Medicine Products: